ARK sells Eli Lilly, buys Tempus AI and Coinbase

Cathie Wood’s ARK Investment Management has adjusted its portfolio, selling shares of Eli Lilly while adding positions in Tempus AI and Coinbase. The move reflects the firm’s active approach to managing its exchange-traded funds and its willingness to rotate holdings as investment views evolve.

Eli Lilly has been a major beneficiary of investor enthusiasm around obesity and diabetes treatments, making it a notable holding for many growth-focused funds. ARK’s decision to exit the drugmaker suggests the firm is reallocating capital toward areas it considers more closely tied to its innovation thesis. The shift also underscores how quickly thematic fund managers can change course when valuations or opportunities shift.

Tempus AI operates at the intersection of artificial intelligence and healthcare, an area that fits ARK’s long-standing focus on disruptive technologies. Coinbase, meanwhile, offers exposure to the digital-asset economy, a sector that has frequently appeared in ARK’s research and portfolio decisions.

The trades highlight how ARK continues to favor companies linked to AI, healthcare innovation and crypto infrastructure. Because the firm publishes its trading activity regularly, its position changes are closely watched by investors seeking insight into Wood’s current priorities and the themes driving her funds.